A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

Stopped Study has crossed the pre-defined futility boundary at the Interim Analysis.

Conditions

• Squamous Cell Carcinoma of the Head and Neck

Interventions

• DRUG: Xevinapant (Debio 1143)
• DRUG: Cisplatin
• RADIATION: Intensity Modulation Radiation Therapy (IMRT)
• DRUG: Placebo

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

• [object Object]
• [object Object]